Candel Therapeutics, Inc. - Common Stock, $0.01 par value per share (CADL)
CUSIP: 137404109
Q3 2021 13F Holders as of 30 Sep 2021
- Type / Class
- Equity / Common Stock, $0.01 par value per share
- Shares outstanding
- 73,303,785
- Total 13F shares
- 4,884,284
- Share change
- +4,072,547
- Total reported value
- $52,945,000
- Price per share
- $10.84
- Number of holders
- 12
- Value change
- +$44,146,000
- Number of buys
- 11
Quarterly Holders Quick Answers
What is CUSIP 137404109?
CUSIP 137404109 identifies CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q4 2021
Recent filing periods for CUSIP 137404109:
Top shareholders of CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Udi Meirav |
3/4/5
|
Director |
—
class O/S missing
|
48,822
|
$43,940 | — | 26 Jul 2021 | |
| SMITH ALAN E |
3/4/5
|
Director |
—
class O/S missing
|
32,548
|
$29,293 | — | 26 Jul 2021 | |
| Nathan Caffo |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
6,000
|
$5,400 | — | 29 Jul 2021 |
Institutional Holders of Candel Therapeutics, Inc. - Common Stock, $0.01 par value per share (CADL) as of Q3 2021
As of 30 Sep 2021,
Candel Therapeutics, Inc. - Common Stock, $0.01 par value per share (CADL) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,884,284 shares.
The largest 10 holders included
FMR LLC, FRANKLIN RESOURCES INC, Sands Capital Ventures, LLC, VANGUARD GROUP INC, Woodline Partners LP, CAAS CAPITAL MANAGEMENT LP, STATE STREET CORP, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
12
institutional shareholders reporting positions in this security
for the Q3 2021 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2021 vs Q4 2025 Across Filers
Q4 2025 holders
84
Q3 2021 holders
12
Holder diff
-72
| Investor | Q4 2025 Shares | Q3 2021 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q3 2021 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.